Aclidinium bromide

(Tudorza Pressair®)

Aclidinium bromide

Latest News

loading GIF

Drug updated on 4/15/2024

Dosage FormPowder (inhalation; 400 mcg)
Drug ClassAnticholinergics
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Aclidinium bromide (Tudorza Pressair) is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). When used in combination with Formoterol, it appears to be the most effective among evaluated treatments in terms of improving Forced Expiratory Volume in the first second (FEV1), a standard measure of lung function.
  • The analysis was based on one systematic review/meta-analysis that included 23 randomized controlled trials involving 20,853 patients, providing robust data on aclidinium bromide's efficacy and safety profile.
  • Other drug combinations such as Umeclidinium/vilanterol and Glycopyrrolate Formoterol Fumarate were also found to be effective but slightly less so than aclidinium bromide/Formoterol. These findings suggest Tudorza Pressair may be among the top choices for COPD management due to its superior performance in enhancing breathing capacity.
  • Monoclonal antibodies like Dupilumab showed good safety profiles compared to placebo despite being less efficacious at improving FEV1. They highlight significant clinical potential for COPD treatment, possibly serving as alternative or adjunct therapies for specific patient subgroups or those with particular safety considerations.
  • Although no direct details on population types or subgroups are provided within this study, it encompasses a large sample size suggesting broad applicability across diverse COPD patient populations. Therefore, these conclusions can potentially guide decisions across various demographic groups affected by COPD.
  • In conclusion, Tudorza Pressair stands out both in terms of efficacy and safety when compared against other conventional combinations and monoclonal antibodies, making it an optimal choice for managing symptoms associated with chronic obstructive pulmonary disease based on current evidence available.

Product Monograph / Prescribing Information

Document TitleYearSource
Tudorza Pressair (aclidinium bromide) Prescribing Information.2021AstraZeneca Pharmaceuticals LP, Wilmington, DE

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines

Document TitleYearSource
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease.2023Global Initiative for Chronic Obstructive Lung Disease
Pocket guide to COPD diagnosis, management, and prevention.2023Global Initiative for Chronic Obstructive Lung Disease
2023 Canadian thoracic society guideline on pharmacotherapy in patients with stable COPD.2023Canadian Journal of Respiratory, Critical Care, and Sleep Medicine
Global strategy for prevention, diagnosis and management of COPD. 2021Global Initiative for Chronic Obstructive Lung Disease
Global initiative for chronic obstructive lung disease: pocket guide to COPD.2021Global Initiative for Chronic Obstructive Lung Disease
Canadian thoracic society clinical practice guideline on pharmacotherapy in patients with COPD – 2019 update of evidence.2019Canadian Journal of Respiratory, Critical Care, and Sleep Medicine
Fixed-dose combinations of long-acting bronchodilators for the management of COPD: Global and Asian perspectives.2019Advances in Therapy